Posted by Michael Wonder on 20 Apr 2020
Epidyolex is granted temporary subsidy
20 April 2020 - The TLV has decided that Epidyolex 100 mg /mL oral solution should be included in the high-cost protection until the ordinary grant application has been tested.
The temporary subsidy includes patients who are already licensed with Epidyolex.
Epidyolex is intended to be used as adjunctive therapy for seizures, in combination with clobazam, in patients from two years of age. Epidyolex has been printed on a so-called license in Sweden. In September 2019, Epidyolex was approved by the European Medicines Agency EMA and thus the drug could no longer be licensed. In April 2020, the company that markets Epidyolex applied for subsidy for the drug from TLV.
